Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up

Abstract 679 Chronic ITP is an autoimmune disease characterized by low platelet counts due to both increased platelet destruction and suboptimal platelet production. Immunosuppressive ITP therapies have variable response rates and may be associated with substantial side effects, limiting their use f...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2009-11, Vol.114 (22), p.679-679
Main Authors: Kuter, David J, Rummel, Mathias J, Boccia, Ralph Vincent, Macik, B. Gail, Pabinger, Ingrid, Selleslag, Dominik L.D., Rodeghiero, Francesco, Chong, Beng H, Müller-Beiβenhirtz, H., Gehl, Lara, Wang, Xuena, Berger, Dietmar
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 679 Chronic ITP is an autoimmune disease characterized by low platelet counts due to both increased platelet destruction and suboptimal platelet production. Immunosuppressive ITP therapies have variable response rates and may be associated with substantial side effects, limiting their use for long-term treatment. Romiplostim is a novel peptibody that increases platelet counts by a mechanism similar to thrombopoietin, and is approved for the treatment of chronic ITP. We present final results from a phase 3b, randomized, open-label study, comparing the incidence of splenectomy and treatment failure in adult nonsplenectomized ITP patients receiving either romiplostim or medical standard of care (SOC). Patients were randomized (2:1) to romiplostim or SOC. Eligible patients had a platelet count
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V114.22.679.679